基于药物基因组学的选择性5-羟色胺再摄取抑制剂个体化治疗抑郁症  

Individualized Therapy Depression of Selective Serotonin Reuptake Inhibitors Based on Pharmacogenomics

作　　者：周长凯[1] 徐龙[1] 张斌[1] 纪洪艳 邢晓敏[1] 郭切[1] 张莎莎[1] 王文晓 邵延琳 于红霞[1] 李静[1] 荆凡波[1] ZHOU Changkai;XU Long;ZHANG Bin;JI Hongyan;XING Xiaomin;GUO Qie;ZHANG Shasha;WANG Wenxiao;SHAO Yanlin;YU Hongxia;LI Jing;JING Fanbo(Department of Pharmacy, the Affiliated Hospital of Qingdao University,Qingdao 266000,China)

机构地区：[1]青岛大学附属医院药学部,青岛266000

出　　处：《医药导报》2021年第2期198-203,共6页Herald of Medicine

基　　金：国家软科学研究计划项目(2010GXS5D231);中国药学会科普研究重点项目(CMEI2020KPYJ00608)。

摘　　要：选择性5-羟色胺再摄取抑制剂(SSRIs)是当前治疗抑郁症的一线药物,CYP2D6、CYP2C19基因多态性会影响SSRIs的代谢,进而影响其疗效与安全性。目前我国临床医师对抑郁症患者基于基因多态性的SSRIs个体化治疗实践相对较少。该文就CYP2D6、CYP2C19基因型及其对SSRIs治疗的影响进行综述,以期为抑郁患者的个体化治疗提供参考。Selective serotonin reuptake inhibitors(SSRIs)are the first-line drugs in the treatment of depression.CYP2D6 and CYP2C19 gene polymorphisms may influence the metabolism of SSRIs.Thereby,they could affect drug safety and efficacy.At present,clinicians have few individualized SSRIs treatment practices for depression patients based on pharmacogenomics.This paper reviews the genotypes of CYP2D6 and CYP2C19 and their effects on SSRIs treatment,in order to provide a useful reference of individualized SSRIs for patients with depression.

关 键 词：选择性5-羟色胺再摄取抑制剂 个体化治疗 药物基因组学 抑郁症 

分 类 号：R971.43[医药卫生—药品]